Can a tailored Blood-Thinner combo prevent second heart attacks without causing bleeding?

This trial tests whether adding a low-dose blood thinner (rivaroxaban) to standard antiplatelet therapy for the first three months after a heart stent procedure can reduce the risk of future heart attacks, strokes, and other cardiovascular events in high-risk patients. Participants are selected based on elevated D-dimer levels or a high PARIS risk score, indicating increased clotting risk. The study compares this short-term triple therapy followed by standard dual antiplatelet therapy against standard dual antiplatelet therapy alone, while closely monitoring for bleeding complications.